CRMD

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Headquartered in Bridgewater, New Jersey, the company's lead product is DefenCath, a novel antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in patients receiving chronic hemodialysis. CorMedix has received FDA approval for DefenCath and is working on commercialization and market penetration. The company is also exploring additional applications for its taurolidine-based platform technology.